Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

NCT05709093 is registered in ClinicalTrials.gov with TJ Biopharma Co., Ltd. as lead sponsor.

NCT NCT05709093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05709093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
Lead sponsor
TJ Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
March 30, 2023
Completion date
April 1, 2024
Enrollment
10 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes(mds)